Data availability
The datasets generated during and/or analyzed during the current study are not publicly available due to patient privacy concerns but are available from the corresponding author on reasonable request.
References
Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121:2186–98.
Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504–10.
Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333.
Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408–17.
Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020;34:1407–21.
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–36.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
Garcia-Gisbert N, Arenillas L, Roman-Bravo D, Rodriguez-Sevilla JJ, Fernandez-Rodriguez C, Garcia-Avila S, et al. Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia. Leukemia. 2022;36:2922–6.
Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 2019;3:339–49.
Acknowledgements
This work was supported in part by the University of Texas MD Anderson Cancer Center Support Grant CA016672 (all authors) and the University of Texas MD Anderson MDS/AML Moon Shot (GM-B, RK-S, CBB, CC, KT, KAS, CB-R, HK, and GG-M). JJR-S is a recipient of MD Anderson’s Odyssey Fellowship.
Author information
Authors and Affiliations
Contributions
G. Montalban-Bravo, J.J. Rodriguez-Sevilla and G. Garcia-Manero designed the study, analyzed the data and participated in writing the manuscript. K. Sasaki, F. Ravandi, N. Daver, K. Takahashi, D. Hammond, K. Chien, N. J. Short, C. DiNardo, E. Jabbour, G. Borthakur, N. Pemmaraju, T. Kadia, G. C. Issa, H. Kantarjian and G. Garcia-Manero contributed patients and participated in analyzing the data and writing the manuscript. S. Pierce collected and analyzed data. S. Loghavi and R. Kanagal-Shamanna performed histopathological analysis and sequencing analysis. D. M Swanson developed mixture and time-to-event models. R Kanagal-Shamanna, S. Loghavi and C. Bueso-Ramos reviewed bone marrow morphologic and genetic findings, analyzed the data and contributed in writing the manuscript.
Corresponding author
Ethics declarations
Competing interests
KS declares honoraria from Otsuka Pharma, and consultancy fee from Pfizer Japan. MK declares consulting and honoraria from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, and Kisoji; research funding and/or clinical trial support from AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, and Astra Zeneca; and stock options/royalties from Reata Pharmaceutical. HK declares research support from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer, honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda, and an advisory role with Actinium. GG-M declares support from and an advisory role with Celgene Corporation, Astex, and Amphivena, and grant/research support 15 from Helsinn, Novartis, AbbVie, Onconova, H3 Biomedicine, and Merck. The rest of authors declare no competing financial interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Montalban-Bravo, G., Rodriguez-Sevilla, J.J., Swanson, D.M. et al. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38, 1178–1181 (2024). https://doi.org/10.1038/s41375-024-02190-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-024-02190-1
- Springer Nature Limited